Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients

Executive Summary

Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.

You may also be interested in...



Antihypertensive Outcomes Labeling Emphasized By FDA After ALLHAT

FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies

Antihypertensive Outcomes Labeling Emphasized By FDA After ALLHAT

FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies

King Altace Scripts Shift To 10 Mg; Dosage From HOPE Trial Helps Fuel Growth

Prescriptions for King's ACE inhibitor Altace (ramipril) are shifting to the 10 mg strength, the same dose used in the Heart Outcomes Prevention Evaluation study, CEO Jefferson Gregory said

Related Content

UsernamePublicRestriction

Register

PS036720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel